Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesalazine for irritable bowel syndrome
2011-003418-18Phase 2Completed
- Sponsor
- Sahlgrenska University Hospital
- Start
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in irritable bowel syndrome (IBS) comparing Mesalazine (Asacol) with Placebo (2 arms). Primary endpoint: Primary efficacy: global IBS symptom relief. Started Dec 2011; status: completed.
02
Drugs
Salcrozine
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on 2011-003418-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003418-18.